Association of a MET genetic variant with autism-associated maternal autoantibodies to fetal brain proteins and cytokine expression
- PMID: 22833194
- PMCID: PMC3309488
- DOI: 10.1038/tp.2011.48
Association of a MET genetic variant with autism-associated maternal autoantibodies to fetal brain proteins and cytokine expression
Abstract
The contribution of peripheral immunity to autism spectrum disorders (ASDs) risk is debated and poorly understood. Some mothers of children with ASD have autoantibodies that react to fetal brain proteins, raising the possibility that a subset of ASD cases may be associated with a maternal antibody response during gestation. The mechanism by which the maternal immune system breaks tolerance has not been addressed. We hypothesized that the mechanism may involve decreased expression of the MET receptor tyrosine kinase, an ASD risk gene that also serves as a key negative regulator of immune responsiveness. In a sample of 365 mothers, including 202 mothers of children with ASD, the functional MET promoter variant rs1858830 C allele was strongly associated with the presence of an ASD-specific 37+73-kDa band pattern of maternal autoantibodies to fetal brain proteins (P=0.003). To determine the mechanism of this genetic association, we measured MET protein and cytokine production in freshly prepared peripheral blood mononuclear cells from 76 mothers of ASD and typically developing children. The MET rs1858830 C allele was significantly associated with MET protein expression (P=0.025). Moreover, decreased expression of the regulatory cytokine IL-10 was associated with both the MET gene C allele (P=0.001) and reduced MET protein levels (P=0.002). These results indicate genetic distinction among mothers who produce ASD-associated antibodies to fetal brain proteins, and suggest a potential mechanism for how a genetically determined decrease in MET protein production may lead to a reduction in immune regulation.
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3309488/bin/tp201148f1.gif)
![Figure 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3309488/bin/tp201148f2.gif)
![Figure 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3309488/bin/tp201148f3.gif)
Similar articles
-
Autism: maternally derived antibodies specific for fetal brain proteins.Neurotoxicology. 2008 Mar;29(2):226-31. doi: 10.1016/j.neuro.2007.10.010. Epub 2007 Nov 6. Neurotoxicology. 2008. PMID: 18078998 Free PMC article.
-
Autism-specific maternal anti-fetal brain autoantibodies are associated with metabolic conditions.Autism Res. 2017 Jan;10(1):89-98. doi: 10.1002/aur.1657. Epub 2016 Jun 17. Autism Res. 2017. PMID: 27312731 Free PMC article.
-
Maternal autoantibodies in autism.Arch Neurol. 2012 Jun;69(6):693-9. doi: 10.1001/archneurol.2011.2506. Arch Neurol. 2012. PMID: 22689191 Free PMC article. Review.
-
Maternal antibodies from mothers of children with autism alter brain growth and social behavior development in the rhesus monkey.Transl Psychiatry. 2013 Jul 9;3(7):e278. doi: 10.1038/tp.2013.47. Transl Psychiatry. 2013. PMID: 23838889 Free PMC article.
-
Maternal and fetal antibrain antibodies in development and disease.Dev Neurobiol. 2012 Oct;72(10):1327-34. doi: 10.1002/dneu.22052. Epub 2012 Sep 4. Dev Neurobiol. 2012. PMID: 22911883 Free PMC article. Review.
Cited by
-
Autism Spectrum Disorder- and/or Intellectual Disability-Associated Semaphorin-5A Exploits the Mechanism by Which Dock5 Signalosome Molecules Control Cell Shape.Curr Issues Mol Biol. 2024 Apr 2;46(4):3092-3107. doi: 10.3390/cimb46040194. Curr Issues Mol Biol. 2024. PMID: 38666924 Free PMC article.
-
Ex vivo exposure to polybrominated diphenyl ether (PBDE) selectively affects the immune response in autistic children.Brain Behav Immun Health. 2023 Oct 28;34:100697. doi: 10.1016/j.bbih.2023.100697. eCollection 2023 Dec. Brain Behav Immun Health. 2023. PMID: 38020477 Free PMC article.
-
Three Decades of Valproate: A Current Model for Studying Autism Spectrum Disorder.Curr Neuropharmacol. 2024;22(2):260-289. doi: 10.2174/1570159X22666231003121513. Curr Neuropharmacol. 2024. PMID: 37873949 Free PMC article. Review.
-
Possible Effect of the use of Mesenchymal Stromal Cells in the Treatment of Autism Spectrum Disorders: A Review.Front Cell Dev Biol. 2022 Jul 5;10:809686. doi: 10.3389/fcell.2022.809686. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 35865626 Free PMC article. Review.
-
Immune Dysregulation in Autism Spectrum Disorder: What Do We Know about It?Int J Mol Sci. 2022 Mar 11;23(6):3033. doi: 10.3390/ijms23063033. Int J Mol Sci. 2022. PMID: 35328471 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous